Cspc Pharmaceutical Group Ltd

Cspc Pharmaceutical Group Ltd maintains a strong liquidity position with a current ratio of 2.19, indicating the company can cover its short-term liabilities more than twice over. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its financial structure. The company's debt-to-equity ratio is 0.02, reflecting a conservative capital structure with minimal leverage. This low debt level supports the company's financial stability and flexibility.

In terms of profitability, Cspc Pharmaceutical Group Ltd reports a return on equity (ROE) of 11.7% and a return on assets (ROA) of 8.31%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns for its shareholders and effectively deploying its assets to generate profit. The operating margin, calculated as operating income divided by revenue, is 18.84%, which is a key performance indicator for pharmaceutical companies and suggests a healthy margin profile.

The company's revenue is primarily concentrated in its domestic market, with a significant portion derived from pharmaceutical products. The financial data does not provide a detailed breakdown of geographic revenue distribution, but the company's operations are largely focused in China. This concentration may expose the company to regulatory and economic risks specific to the Chinese market, but it also allows for a focused strategy in a large and growing pharmaceutical market.

Looking at the company's growth trajectory, the outlook for the current fiscal year indicates a positive direction, with revenue expected to grow. The company's capital expenditure of -2.28 billion CNY suggests a reduction in investment in new projects or facilities, which may indicate a shift in strategic focus or a response to market conditions. The company's free cash flow of 508 million CNY provides flexibility for reinvestment, dividends, or debt reduction, supporting long-term growth and financial health.

The risk assessment for Cspc Pharmaceutical Group Ltd indicates a low dilution risk, with a dilution score of low. The company's capital structure is stable, and there is no indication of imminent dilution from new share issuances or convertible instruments. The risk assessment also highlights a key flag: net cash is negative after subtracting total debt, which may indicate a need for careful cash flow management. However, the company's strong operating cash flow of 5.83 billion CNY provides a buffer against liquidity constraints.

Recent events and filings do not indicate any major disruptions or strategic shifts for Cspc Pharmaceutical Group Ltd. The company's financial performance and market position remain stable, with analyst estimates suggesting a mean price target of 11.25 CNY and a median price target of 11.20 CNY. The mean recommendation of 2.40, with 4 strong-buy ratings, 12 buy ratings, and 6 hold ratings, indicates a generally positive outlook from analysts.